U.S. Pharmaceutical Sales - Q4 2013
The following is a list of the top 100 prescribed medicines by U.S. National Sales in Q4 2013. Figures include sales through both retail and hospital channels, listed by drug name and sales value in U.S. dollars. See also: Top 100 drugs for 2013
Last updated: February 2014 (updated quarterly).
Top 100 Drugs for Q4 2013 by Sales
- Sales Statistics Q4 2013
- Units*
| Rank |
Drug |
Sales ($000) |
|
|
| 1 |
Abilify
Otsuka Pharmaceutical Co., Ltd |
1,602,329 |
2.23% |
Stats |
| 2 |
Nexium
AstraZeneca |
1,536,435 |
0.74% |
Stats |
| 3 |
Humira
AbbVie Inc. |
1,461,861 |
3.86% |
Stats |
4 ( 1) |
Crestor
AstraZeneca |
1,333,502 |
4.53% |
Stats |
| 5 (1) |
Advair Diskus
GlaxoSmithKline |
1,247,330 |
2.65% |
Stats |
| 6 (1) |
Enbrel
Amgen Inc. |
1,189,844 |
1.46% |
Stats |
7 ( 3) |
Cymbalta
|
1,064,186 |
-23.06% |
Stats |
| 8 |
Remicade
Janssen Pharmaceuticals, Inc. |
994,020 |
-2.71% |
Stats |
| 9 |
Neulasta
Amgen Inc. |
854,508 |
-4.90% |
Stats |
| 10 |
Copaxone
Teva Pharmaceuticals USA, Inc. |
851,351 |
-4.69% |
Stats |
| 11 (1) |
Lantus Solostar
Sanofi |
839,691 |
9.39% |
Stats |
| 12 (1) |
Rituxan
Genentech, Inc. |
798,989 |
1.25% |
Stats |
| 13 |
Spiriva
Boehringer Ingelheim Pharmaceuticals, Inc. |
746,766 |
-0.16% |
Stats |
| 14 (1) |
Januvia
Merck |
700,941 |
3.63% |
Stats |
| 15 (1) |
Atripla
Gilead Sciences, Inc. |
679,418 |
0.36% |
Stats |
| 16 (1) |
Lantus
Sanofi |
675,461 |
5.84% |
Stats |
| 17 (1) |
Avastin
Genentech, Inc. |
650,208 |
-1.25% |
Stats |
| 18 |
Lyrica
Pfizer Inc. |
624,774 |
2.82% |
Stats |
| 19 |
OxyContin
Purdue Pharma LP |
585,482 |
-2.91% |
Stats |
| 20 |
Epogen
Amgen Inc. |
580,570 |
1.54% |
Stats |
| 21 |
Celebrex
Pfizer Inc. |
580,332 |
5.23% |
Stats |
| 22 |
Truvada
Gilead Sciences, Inc. |
542,846 |
0.03% |
Stats |
| 23 |
Diovan
Novartis Pharmaceuticals Corporation |
533,924 |
2.80% |
Stats |
| 24 (1) |
Gleevec
Novartis Pharmaceuticals Corporation |
498,149 |
7.22% |
Stats |
| 25 (1) |
Herceptin
Genentech, Inc. |
473,632 |
1.53% |
Stats |
| 26 |
Lucentis
Genentech, Inc. |
460,621 |
-0.84% |
Stats |
| 27 (2) |
Vyvanse
Takeda Pharmaceutical Company Limited |
447,188 |
9.39% |
Stats |
| 28 |
Zetia
Merck |
444,731 |
4.04% |
Stats |
| 29 (2) |
Namenda
Allergan plc |
434,766 |
-6.00% |
Stats |
| 30 |
Levemir
Novo Nordisk |
424,186 |
9.34% |
Stats |
| 31 (1) |
Symbicort
AstraZeneca |
407,646 |
9.63% |
Stats |
| 32 (5) |
Tecfidera
Biogen |
391,404 |
20.28% |
Stats |
33 ( ) |
ONE TOUCH ULTRA
|
370,899 |
n/a |
Stats |
| 34 (1) |
NovoLog FlexPen
Novo Nordisk |
364,870 |
7.84% |
Stats |
| 35 (1) |
AndroGel
AbbVie Inc. |
351,737 |
5.47% |
Stats |
| 36 (1) |
Novolog
Novo Nordisk |
344,235 |
3.86% |
Stats |
| 37 (1) |
enoxaparin
Generic |
341,184 |
6.55% |
Stats |
| 38 (1) |
methylphenidate
Generic |
327,346 |
2.26% |
Stats |
| 39 (3) |
Suboxone
|
321,892 |
-2.11% |
Stats |
| 40 (10) |
Xarelto
|
321,462 |
18.72% |
Stats |
| 41 (7) |
ProAir HFA
Teva Pharmaceuticals USA, Inc. |
306,461 |
10.87% |
Stats |
| 42 (1) |
Humalog
Eli Lilly and Company |
304,866 |
6.15% |
Stats |
| 43 (3) |
Alimta
Eli Lilly and Company |
302,728 |
6.00% |
Stats |
| 44 (5) |
Victoza
Novo Nordisk |
301,414 |
9.59% |
Stats |
| 45 (3) |
Viagra
Pfizer Inc. |
300,463 |
3.26% |
Stats |
| 46 (1) |
Seroquel XR
AstraZeneca |
291,494 |
2.22% |
Stats |
| 47 () |
Synagis
MedImmune, Inc. |
289,704 |
n/a |
Stats |
| 48 (3) |
Avonex
Biogen |
281,554 |
-1.43% |
Stats |
| 49 (19) |
Renvela
Sanofi |
280,917 |
21.44% |
Stats |
| 50 (9) |
Rebif
EMD Serono, Inc. |
280,548 |
-6.27% |
Stats |
| 51 (1) |
Cialis
Eli Lilly and Company |
280,518 |
4.58% |
Stats |
| 52 (1) |
Gilenya
Novartis Pharmaceuticals Corporation |
272,701 |
4.05% |
Stats |
| 53 (1) |
Nasonex
Merck |
272,345 |
5.67% |
Stats |
| 54 (8) |
Stelara
Janssen Pharmaceuticals, Inc. |
270,598 |
12.47% |
Stats |
| 55 (2) |
Restasis
Allergan plc |
268,463 |
6.30% |
Stats |
| 56 (22) |
budesonide
Generic |
268,201 |
26.81% |
Stats |
| 57 (2) |
acetaminophen/hydrocodone
Generic |
264,814 |
6.67% |
Stats |
| 58 (11) |
Flovent HFA
GlaxoSmithKline |
263,072 |
13.97% |
Stats |
| 59 (1) |
Lovaza
GlaxoSmithKline |
258,177 |
2.90% |
Stats |
| 60 (1) |
Prezista
Janssen Pharmaceuticals, Inc. |
251,372 |
3.54% |
Stats |
| 61 (1) |
Isentress
Merck |
248,924 |
0.72% |
Stats |
| 62 (4) |
Janumet
Merck |
247,150 |
4.65% |
Stats |
| 63 (12) |
Procrit
Janssen Pharmaceuticals, Inc. |
241,535 |
-10.09% |
Stats |
| 64 (9) |
doxycycline
Generic |
241,381 |
-5.65% |
Stats |
| 65 (1) |
Orencia
Bristol-Myers Squibb Company |
241,149 |
1.65% |
Stats |
| 66 (1) |
amphetamine/dextroamphetamine
Generic |
240,482 |
2.78% |
Stats |
| 67 (4) |
VESIcare
Astellas Pharma US, Inc. |
240,435 |
5.37% |
Stats |
| 68 (4) |
Dexilant
Takeda Pharmaceutical Company Limited |
238,897 |
7.57% |
Stats |
| 69 (7) |
Humalog KwikPen
Eli Lilly and Company |
238,418 |
11.02% |
Stats |
| 70 (5) |
Neupogen
Amgen Inc. |
229,912 |
-2.70% |
Stats |
| 71 () |
lidocaine
Generic |
225,903 |
n/a |
Stats |
| 72 (5) |
Lunesta
Sunovion Pharmaceuticals Inc. |
225,101 |
5.24% |
Stats |
| 73 (3) |
fenofibrate
Generic |
223,300 |
-2.22% |
Stats |
| 74 (12) |
Zytiga
Janssen Pharmaceuticals, Inc. |
222,026 |
11.86% |
Stats |
| 75 (2) |
Reyataz
Bristol-Myers Squibb Company |
217,793 |
-1.38% |
Stats |
| 76 (15) |
Sensipar
Amgen Inc. |
216,657 |
13.71% |
Stats |
| 77 (2) |
metoprolol
Generic |
215,111 |
2.99% |
Stats |
| 78 (11) |
Invega Sustenna
Janssen Pharmaceuticals, Inc. |
214,251 |
10.03% |
Stats |
| 79 (4) |
Synthroid
AbbVie Inc. |
213,424 |
-2.50% |
Stats |
| 80 (12) |
Avonex Pen
Biogen |
211,917 |
13.59% |
Stats |
| 81 (7) |
Prevnar 13
Pfizer Inc. |
209,367 |
6.41% |
Stats |
| 82 (1) |
Xolair
|
207,891 |
1.91% |
Stats |
| 83 (2) |
Combivent Respimat
Boehringer Ingelheim Pharmaceuticals, Inc. |
207,542 |
4.23% |
Stats |
| 84 () |
levothyroxine
Generic |
204,755 |
n/a |
Stats |
| 85 (2) |
Benicar
Daiichi Sankyo |
203,336 |
3.22% |
Stats |
| 86 () |
Stribild
Gilead Sciences, Inc. |
202,642 |
n/a |
Stats |
| 87 (12) |
Zostavax
Merck |
202,240 |
15.17% |
Stats |
| 88 (4) |
Pradaxa
Boehringer Ingelheim Pharmaceuticals, Inc. |
200,697 |
-0.53% |
Stats |
| 89 (9) |
Vytorin
Merck |
199,625 |
-3.02% |
Stats |
| 90 () |
Tamiflu
|
197,718 |
n/a |
Stats |
| 91 (1) |
Xgeva
Amgen Inc. |
197,711 |
3.24% |
Stats |
| 92 (11) |
Evista
|
196,929 |
-4.31% |
Stats |
| 93 (2) |
Xeloda
Genentech, Inc. |
194,044 |
6.52% |
Stats |
| 94 (12) |
Aranesp
Amgen Inc. |
185,225 |
-9.22% |
Stats |
| 95 () |
Ventolin HFA
GlaxoSmithKline |
183,060 |
n/a |
Stats |
| 96 () |
divalproex sodium
Generic |
181,554 |
n/a |
Stats |
| 97 (1) |
Afinitor
Novartis Pharmaceuticals Corporation |
180,719 |
0.03% |
Stats |
| 98 (5) |
Betaseron
Bayer HealthCare Pharmaceuticals Inc. |
179,216 |
-3.72% |
Stats |
| 99 (1) |
Adderall XR
Takeda Pharmaceutical Company Limited |
177,505 |
3.31% |
Stats |
| 100 () |
Complera
Gilead Sciences, Inc. |
174,933 |
n/a |
Stats |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
